Search
Clinician Ordering Portal
Scientific evidence
Tissue systems pathology test objectively risk stratifies Barrett’s esophagus patients with low-grade dysplasia
Apr 2021
The risk prediction assay provided significant risk stratification in BE patients with LGD and identified progressors that the experts downstaged to NDBE.
Publication: American Journal of Gastroenterology
Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma
Apr 2021
Prospective analysis reporting long-term outcomes for patients tested with DecisionDx-Melanoma (follow-up to study first published as Hsueh, 2017).
Publication: JCO Precision Oncology
The TissueCypher® Barrett’s esophagus assay impacts clinical decisions in the management of patients with Barrett’s esophagus
Mar 2021
The TissueCypher test may enable physicians to target EET for high-risk BE patients, while reducing unnecessary procedures in low-risk patients.
Publication: Endoscopy International Open
Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy
Mar 2021
GEP class was predictive of RFS and DMFS and independently predicted relapse in AJCC “low risk” (stages IA-IIA) patients.
Publication: The American Jounral of Surgery
Assessment of the 31-gene expression profile test by dermatologists: a cross-sectional survey from national dermatology conferences
Mar 2021
Survey to assess the professional understanding, opinions, and clinical usage of the 31-GEP test by dermatologists.
Publication: SKIN: Journal of Cutaneous Melanoma
Risk stratification of patients with stage I cutaneous melanoma using 31-gene expression profiling
Jan 2021
Examined the prognostic value of the 31-gene expression profile (31-GEP) test for the risk of recurrence in stage I CM patients according to 31-GEP class.
Publication: Journal of Clinical and Aesthetic Dermatology
A dermatologist’s guide to implementation of gene expression profiling in the management of melanoma
Nov 2020
Expert panel of 5 leading dermatologists with 31-GEP experience convened to review literature and create a shared decision-making model/algorithm.
Publication: Journal of Clinical and Aesthetic Dermatology
Independent validation of a tissue systems pathology assay to predict future progression in non-dysplastic Barrett’s esophagus: a spatial-temporal analysis
Oct 2020
Assessing additional spatial and temporal biopsies increased the predictive accuracy, allowing for identification of most future progressors.
Publication: Clinical and Translational Gastroenterology
Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations
Oct 2020
Define changes in clinical management resulting from the use of the prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma in a surgical oncology practice.
Publication: Future Oncology
Instrument gauge and type in uveal melanoma fine needle biopsy: implications for diagnostic yield and molecular prognostication
Aug 2020
Purpose: To systematically evaluate and compare the effects of using small-gauge needles and vitrectors on the ability to obtain adequate diagnostic and prognostic uveal melanoma biopsy specimens.
Publication: American Journal of Ophthalmology
Integration of a 31-gene expression profile into clinical decision-making in the treatment of cutaneous melanoma
Aug 2020
Retrospective review and early experience in utilizing 31-GEP in intermediate melanomas and its effect on clinical management.
Publication: The American Surgeon
Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis
Jul 2020
The prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) predicts metastatic risk based on primary tumor biology. Here we report outcomes from a prospective registry of 15-GEP-tested patients, and a meta-analysis with published cohorts.
Publication: Ocul Oncol Pathol